End-to-end platform tailored for the hospital’s vascular care team helps detect suspected vascular disease and improve patient outcomes
News | Artificial Intelligence
Delray Medical Center Advances its Endovascular Program as the First Hospital in Florida to Acquire the AI-Powered Viz Vascular Suite

December 19, 2022 — As a leader in vascular care, Delray Medical Center is the first hospital in Florida to acquire the ...

Home December 19, 2022
Home
suPAR overexpression leads to increased atherosclerotic and necrotic plaques in a murine model of atherosclerosis. WT (n = 18) and suPARTg (n = 21) mice were maintained on a low-fat diet until 3 months of age and were then transfected with Pcsk9-AAV and fed a western diet (WD) for 10 weeks. At this point, aortic roots were obtained, paraffin embedded, and stained with H&E and Mac2 (galectin 3). (A) Cross sections of aortic roots from C57BL/6 WT and suPARTg mice show total lesion area, outlined in dashed lin
News | Heart Failure
New Immune Target to Treat Cardiovascular Disease Discovered

December 16, 2022 — For the longest time, clinicians have treated cardiovascular disease by focusing on diabetes and ...

Home December 16, 2022
Home
From left, Craig Schumacher, Jake and Yvette Honda-Schumacher. Image courtesy of Cedars-Sinai
News | Pediatric Cardiology
A Heart Fix That Fits

December 16, 2022 — Yvette Honda-Schumacher was 20 weeks pregnant and had just had a routine anatomy ultrasound when she ...

Home December 16, 2022
Home
Innovative approach can deliver high-fidelity cardiopulmonary exercise test results comparable to gold-standard testing with a wearable sensor during routine daily activities
News | Remote Monitoring
physIQ’s eVO2Max Demonstrates Breakout Ability to Estimate Cardiopulmonary Functional Capacity from Wearable Sensor Data During Daily Routine Activity

December 15, 2022 — physIQ announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable ...

Home December 15, 2022
Home
Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.
News | STEMI
Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 — Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

Home December 15, 2022
Home
From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University
News | Heart Failure
New Target in the Fight Against Heart Disease

December 15, 2022 — Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your ...

Home December 15, 2022
Home
Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).
News | Heart Valve Technology
Edwards Identifies Top Data Releases of 2022 that Highlight the Impacts of Aortic Stenosis Undertreatment

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping ...

Home December 14, 2022
Home
Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).
News | Stroke
Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing ...

Home December 14, 2022
Home
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
News | Atrial Fibrillation
Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

December 14, 2022 — Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of ...

Home December 14, 2022
Home
Corindus, A Siemens Healthineers Company, has officially rebranded as Siemens Healthineers
News | Cardiovascular Business
Corindus, A Siemens Healthineers Company, Is Now Siemens Healthineers Endovascular Robotics

December 14, 2022 — Corindus, A Siemens Healthineers Company, has been rebranded to Siemens Healthineers Endovascular ...

Home December 14, 2022
Home
Series to feature leading experts discussing the current and future trends in the carotid treatment market
News | Stents Carotid
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home December 13, 2022
Home
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
News | Structural Heart
Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
Image courtesy of Intermountain Healthcare
News | Cardiovascular Clinical Studies
Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
Home
The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between 2022 and 2025, driven by increasing population at a risk of cardiovascular diseases.
News | Pacemakers
Global Pacemakers Market Set to Grow at 5.4% CAGR Over Next 3 Years

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

Home December 12, 2022
Home
Michael A. Mussallem
News | Cardiovascular Business
Edwards Lifesciences Announces CEO Succession Plan

December 12, 2022 — Edwards Lifesciences Corporation announced that following regular succession planning discussions ...

Home December 12, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now